Pharma gets 4 extra years of monopoly pricing on genetic drugs
H.R. 1672 — Maintaining Investments in New Innovation Act · Filed by Donald Davis (D-NC) · 49 cosponsors · Introduced Feb 27, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends the patent-like exclusivity period for certain drugs from 7 years to 11 years if they use genetically targeted technology—meaning drugs designed to work on specific genetic profiles. The extension applies to 'advanced drug products' that modulate gene function. This gives pharmaceutical companies a longer period during which generic competitors cannot enter the market for these drugs.
Why we flagged it
The bill's operative mechanism is a straightforward extension of market exclusivity for a defined class of drugs. It is not disguised, but the title 'Maintaining Investments in New Innovation' obscures the actual effect—a monopoly-pricing extension—by framing it as innovation support rather than a delay of generic competition.
What the text implies
- The 4-year exclusivity extension applies regardless of whether the genetic targeting represents genuine innovation or marginal modification of existing drugs, creating incentive to add genetic-targeting claims to existing therapies to qualify for extended exclusivity.
- Medicare and Medicaid, which serve elderly and low-income populations, will bear disproportionate cost burden during the extended exclusivity period, as these programs cover high volumes of prescription drugs and cannot easily negotiate prices during exclusivity.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical companies developing genetically targeted drugs; biotechnology firms with genetic-targeting platforms